Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study.

MLA

Joly, Pascal, et al. “Tacrolimus 0.1% versus Ciclopiroxolamine 1% for Maintenance Therapy in Patients with Severe Facial Seborrheic Dermatitis: A Multicenter, Double-Blind, Randomized Controlled Study.” Journal of the American Academy of Dermatology, vol. 84, no. 5, May 2021, pp. 1278–84. EBSCOhost, https://doi.org/10.1016/j.jaad.2020.09.055.

APA

Joly, P., Tejedor, I., Tetart, F., Cailleux, H. C., Barrel, A., De Preville, P. A., Mion-Mouton, N., Gabison, G., Baricault, S., Tordeur, C. G., Dore, M. X., Rossi, B., Bourseau-Quetier, C., Chamaillard, M., Ly, S., Chosidow, O., Richard-Lallemand, M.-A., Rzeznik, J.-C., Amici, J.-M., … Beylot-Barry, M. (2021). Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study. Journal of the American Academy of Dermatology, 84(5), 1278–1284. https://doi.org/10.1016/j.jaad.2020.09.055

Chicago

Joly, Pascal, Ines Tejedor, Florence Tetart, Hélène Collas Cailleux, Alice Barrel, Paul Arnaud De Preville, Nathalie Mion-Mouton, et al. 2021. “Tacrolimus 0.1% versus Ciclopiroxolamine 1% for Maintenance Therapy in Patients with Severe Facial Seborrheic Dermatitis: A Multicenter, Double-Blind, Randomized Controlled Study.” Journal of the American Academy of Dermatology 84 (5): 1278–84. doi:10.1016/j.jaad.2020.09.055.